China's Puncture Robotics Firm True Health Files For Hong Kong IPO

Guangdong true Health Medical Technology, a Chinese medical robotics company specializing in puncture and ablation robots, has filed for a Hong Kong IPO to fund development and commercialization. While the company leads China's niche puncture robotics market with regulatory approvals, it faces significant challenges including minimal revenue (173,000 yuan in H1 2025), heavy dependence on a single customer for 90% of revenue, and substantial net losses (56.73 million yuan in H1 2025). The market for puncture robots is projected to grow significantly but remains in early stages.